Press release
Chagas Disease Pipeline Assessment Report (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Mitsubishi Tanabe Pharma Corporation, Eisai Co Ltd, Selva Therapeutics, ConserV Bioscience, Seren Pharmaceuticals, 7 Hills Pharma
"Chagas Disease Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chagas Disease Therapeutics Market.
The report provides a detailed description of the Chagas Disease drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Chagas Disease Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/chagas-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Chagas Disease Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Chagas Disease therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chagas Disease treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Chagas Disease drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Chagas Disease treatment market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Commercial Development Activities in the Chagas Disease Therapeutics Domain:
https://www.delveinsight.com/report-store/chagas-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Chagas Disease Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Chagas Disease Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Chagas Disease. Currently, Seren Pharmaceuticals is leading the therapeutics market with its Chagas Disease drug candidates in the most advanced stage of clinical development.
Request for Sample PDF to Understand More About the Chagas Disease Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/chagas-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Chagas Disease Companies in the Therapeutics Market Include:
• Mitsubishi Tanabe Pharma Corporation
• Eisai Co Ltd
• Selva Therapeutics
• ConserV Bioscience
• Seren Pharmaceuticals
• 7 Hills Pharma
And Many Others
Emerging and Marketed Chagas Disease Therapies Covered in the Report Include:
• Fosravuconazole: Seren Pharmaceuticals: Fosravuconazole is a new oral antifungal component developed by Eisai. In 2010, Eisai concluded a license agreement with Seren Pharma, granting them exclusive rights to develop, commercialize, and sublicense the agent in Japan. Fosravuconazole is a prodrug that improves the solubility and bioavailability of ravuconazole, the main active ingredient. When administered to humans, it is rapidly converted to ravuconazole.
Get an in-depth Assessment of the Emerging Therapies and Chagas Disease Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/chagas-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Chagas Disease Current Treatment Patterns
4. Chagas Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chagas Disease Late-Stage Products (Phase-III)
7. Chagas Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chagas Disease Discontinued Products
13. Chagas Disease Product Profiles
14. Chagas Disease Companies
15. Chagas Disease Drugs
16. Dormant and Discontinued Products
17. Chagas Disease Unmet Needs
18. Chagas Disease Future Perspectives
19. Chagas Disease Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/chagas-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Other Trending Healthcare Reports by DelveInsight
Throat Cancer Market
https://www.delveinsight.com/report-store/throat-cancer-market
Nephrosclerosis Market
https://www.delveinsight.com/report-store/nephrosclerosis-market
Nocturnal Enuresis Market
https://www.delveinsight.com/report-store/nocturnal-enuresis-market
Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
Mucinous cystic neoplasms (MCNs) Market
https://www.delveinsight.com/report-store/mucinous-cystic-neoplasms-mcns-market
Adenosine Deaminase-Severe Combined Immunodeficiency Market
https://www.delveinsight.com/report-store/adenosine-deaminase-severe-combined-immunodeficiency-market
Metastatic Cutaneous Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/metastatic-cutaneous-squamous-cell-carcinoma-market
Insulin Glargine Biosimilar
https://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
HDAC Inhibitors Market
https://www.delveinsight.com/report-store/hdac-inhibitors-market
Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
mRNA Vaccine and Therapeutics Market
https://www.delveinsight.com/report-store/mrna-vaccine-and-therapeutics-market
Asthma Diagnostic Devices Market
https://www.delveinsight.com/report-store/asthma-diagnostic-devices-market
Holter Monitor Market
https://www.delveinsight.com/report-store/holter-monitor-market
Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Sacral Nerve Stimulator Devices Market
https://www.delveinsight.com/report-store/sacral-nerve-stimulator-devices-market
Cardiac Monitoring System Market
https://www.delveinsight.com/report-store/cardiac-monitoring-system-market
Implantable Cardioverter Defibrillators (ICDs) Market
https://www.delveinsight.com/report-store/implantable-cardioverter-defibrillators-icds-market
Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market
Breast Pumps Market
https://www.delveinsight.com/report-store/breast-pumps-market
Dental Lasers Market
https://www.delveinsight.com/report-store/dental-lasers-market
Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
Negative Pressure Wound Therapy Systems Market
https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market
India Healthcare Outlook Report
https://www.delveinsight.com/report-store/india-healthcare-outlook-report
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chagas Disease Pipeline Assessment Report (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Mitsubishi Tanabe Pharma Corporation, Eisai Co Ltd, Selva Therapeutics, ConserV Bioscience, Seren Pharmaceuticals, 7 Hills Pharma here
News-ID: 3067050 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Chagas
Chagas Disease Treatment Market: An In-Depth Analysis
The global Chagas Disease Treatment Market was valued at approximately USD 450 million in 2024 and is projected to reach around USD 700 million by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033 .
Chagas Disease Treatment Market Overview
Chagas disease, caused by the Trypanosoma cruzi parasite, remains a significant public health challenge, particularly in Latin America. The market's growth is driven by increasing awareness,…
Chagas Disease Drug Market Size, Share, Growth Forecast 2023-2032
Chagas disease, caused by the parasite Trypanosoma cruzi, remains a significant public health concern, particularly in Latin America. With an estimated 6 to 7 million people worldwide affected by this neglected tropical disease, the demand for effective treatments has spurred the growth of the Chagas Disease Drug Market. As of 2022, the market size stood at a commendable USD 265.2 million, and projections indicate a robust expansion, with expectations to…
Chagas Disease Drug Market Size To Touch USD 520.4 Million By 2032
Chagas Disease Drug Market Size to Occupy More Than USD 520.4 Million by 2032 | CAGR 7.1% from 2023 to 2032
The Chagas Disease Drug Market research report published by Acumen Research and Consulting provides a comprehensive yet detailed analysis of the global market landscape. The report helps our clients understand the market scenario while also providing a detailed historical account of the market over the previous years. The Chagas Disease…
2018 – 2024 Chagas Disease Management Market | Global Industry Report
2018 – 2024 Chagas Disease Management Market | Global Industry Report
A Recent Market Study On Chagas Disease And Its Current Trends And Future Insights
Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. It is transmitted by kissing bugs or triatomine bugs. It can also be transmitted through blood transfusions, in pregnancy, and organ transplantation. In early stage of the Chagas disease, the symptoms include swollen…
Chagas Disease Treatment Market Global Industry Insights, and Forecast till 2025
Chagas disease is an endemic in 21 Latin American countries caused by kinetoplastid protozoan parasite, Trypanosoma cruzi, primarily transmitted by large, blood-sucking reduviid insects widely known as 'the kissing bugs'. Moreover, the disease can be transferred through other means such as blood transfusion, organ transplantation, as well as congenital and oral transmissions. The recent past has witnessed spread of Chagas disease to developed economies such as Europe and North America,…
Chagas Disease Treatment Market - Global Industry Insights, and Forecast till 20 …
Chagas disease is an endemic in 21 Latin American countries caused by kinetoplastid protozoan parasite, Trypanosoma cruzi, primarily transmitted by large, blood-sucking reduviid insects widely known as 'the kissing bugs'. Moreover, the disease can be transferred through other means such as blood transfusion, organ transplantation, as well as congenital and oral transmissions. The recent past has witnessed spread of Chagas disease to developed economies such as Europe and North America,…
